GE Healthcare and Valneva collaboration results in cell culture medium for vaccine production

3 November 2016 (Last Updated November 3rd, 2016 18:30)

GE Healthcare’s Life Sciences business and integrated vaccine biotech company Valneva SE have successfully collaborated to optimise virus productivity in Valneva’s EB66 cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health.

GE Healthcare’s Life Sciences business and integrated vaccine biotech company Valneva SE have successfully collaborated to optimise virus productivity in Valneva’s EB66 cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health.

Viral production in EB66 cells includes secreted viruses, such as measles, alphaviruses, influenza A and B strains, and intracellular viruses, such as the modified vaccinia Ankara (MVA) virus.

This collaboration has led to the creation of a commercial cell culture medium, HyClone CDM4Avian, developed to address the challenges of media variability.

The new medium supports efficient and predictable virus production for manufacturers utilising EB66 cells, helping to  increase production reliability and boost end-product quality.

"The advent of cell-based production is helping manufacturers meet the growing need for vaccines to address global healthcare challenges."

Feasible for use throughout the entire cell-growth process, CDM4Avian is chemically defined and free from animal-derived components, which enhances product consistency and simplifies the regulatory processes for new products developed in EB66 cells.

GE Healthcare Life Sciences upstream and cell culture general manager Morgan Norris said: “Working in close collaboration with Valneva and capturing their expertise in vaccine production has enabled us to successfully enhance productivity and create a novel cell culture medium for a vaccine industry undergoing a period of exciting change.

"The advent of cell-based production is helping manufacturers meet the growing need for vaccines to address global healthcare challenges.”

Valneva president and chief executive officer Thomas Lingelbach and deputy chief executive officer Franck Grimaud said: “This collaboration with GE has been very successful and we are extremely pleased that our EB66 licensees now have access to a medium that will greatly ease the development of their new products.

"Coupled with the recent European Medicine Agency’s (EMA) decision to allow the production of live attenuated vaccines in cell-lines such as EB66, this strongly supports the choice of EB66 as a modern cell technology platform for vaccine development and manufacturing.”

Until now, only inactivated vaccines could be developed in EB66 cells within Europe.

The EMA recently decided to issue new guidelines on vaccine production in immortal cell lines allowing Valneva’s partners to now utilise the EB66 cell line to develop and manufacture live-attenuated vaccines (LAV), including Modified Vaccinia Ankara (MVA)-based vaccines, measles and oncolytic vaccines.